Search

A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.

Our recent research demonstrates that the thrombopoietin receptor agonist romiplostim effectively modifies chemotherapy-induced thrombocytopenia (CIT) in solid tumor patients, allowing a majority to resume chemotherapy

Approaches used for research into the social lives of bacteria can also be used to explore how tumors behave and evolve.

Jeffrey Zwicker, MD, has been named Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from Harvard University Medical School, where he was an Associate Professor of Medicine, and Beth Israel Deaconess Medical Center (BIDMC), where he served as Chief of Benign Hematology in the Division of Hematology since 2017. Dr. Zwicker succeeds MSK’s Interim Hematology Service Chief, Marcel van den Brink, MD, PhD.

In honor of Women's History Month, meet the scientific hero who helped raise money and awareness for AIDS research.

Memorial Sloan Kettering has announced the creation of the Louis V. Gerstner, Jr. Young Investigators Fund and has named the fund's first four recipients.

Researchers found that a common cancer gene called PIK3CA also causes the condition venous malformation. Their discovery has already pointed the way to targeted therapies for this rare and painful condition that affects one in 10,000 people.

Meet MSK Research Scholar Moralba Dominguez Garcia, PhD: “I wanted to do something that creates knowledge — and that can help other people.”